Indaptus Therapeutics, Inc.

US$3.32As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:INDPHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (57.88%)
Div yield —
ROE (318.04%)
Biotechnology
Beta (5Y) 0.94
PE TTM —
TSR TTM 3.11%
Mkt cap US$509.9M
ROIC (113.73%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.82
15.00%
(66.03%)
Hold 0|5|1|12|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.05
(4.70%)
(9.46%)
1.64%
15.40%
Revenue$M
38.72
40.34
39.18
39.56
8.19%
13.26%
6.43%
3.24%
Peers (US$509.9M)
Cap (US$)
PE
506.5M
—
503.9M
—
506.5M
66.46x
Capital
TTM
5Y
10Y
Leveragex
0.644
1.143
0.873
EBIT/Intx
1.355
0.708
0.713
Own earn%
29.80
(102.28)
(80.25)
Sh yield%
36.01
38.69
38.52
Owners
Insiders/Inst%
14.23
36.23
Short interest%
2.03
SBC / revenue%
0.71
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
9–13
$1 testx
—
Incr. ROIC%
1